Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial

Effects of hormonal treatment on nerve fibers in endometrium and myometrium in women with endometriosis

“…Six months of treatment with danazol significantly alleviated endometriosis-associated pelvic pain, lower back pain, and defecation pain (18) and deep dyspareunia (10). Six to 12 months of treatment with a low-dose OC significantly reduced deep dyspareunia and dysmenorrhea in women with endometriosis (10,11). Women with endometriosis who had dysmenorrhea, dyspareunia, and noncyclic pelvic pain had their pain significantly relieved by norethindrone acetate (12), and treatment with dydrogesterone for 6 months also reduced pelvic pain in women with endometriosis (13).…”

“…Several studies have demonstrated the efficacy of drugs for endometriosis-associated pain; treatment with an OC, norethindrone, and dydrogesterone significantly reduced pain symptoms including deep dyspareunia, dysmenorrhea, and pelvic pain in women with endometriosis (10)(11)(12)(13).…”

Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III–IV. A randomized comparative trial

“…Four trials comparing postsurgical estrogen-lowering medical therapies to surgery alone (either no medical therapy or placebo) show no statistically significant reduction in pain recurrence at 12 months (23)(24)(25)(26). On the other hand, other investigators have documented that hormonal therapy suppression after conservative surgery is significantly more likely to have a marked improvement of painful symptoms compared with surgery alone (7,27).…”

Endometriosis - Review Of Current Therapeutic Aproaches For Disease Control

“…Други проучвания сравняват ефикасността на КОК с тази на GnRH-a (14,15). При сравняване на терапията с ниски дози КОК (етинилстрадиол 0,02мг/ дезогестрел 0,15мг) с GnRH-a (госерелин 3,6мг) се констатира намаляване на диспареунията (по-добри показатели за госерелин) и неменструалната тазова болка.…”